Luca Cantarini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5913947/publications.pdf

Version: 2024-02-01

395 papers 13,075 citations

25014 57 h-index 92 g-index

402 all docs 402 docs citations

402 times ranked 10280 citing authors

#	Article	IF	CITATIONS
1	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Annals of the Rheumatic Diseases, 2010, 69, 798-806.	0.5	1,073
2	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases, 2013, 72, 678-685.	0.5	350
3	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.5	300
4	The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Annals of the Rheumatic Diseases, 2014, 73, 2160-2167.	0.5	256
5	Recommendations for the management of autoinflammatory diseases. Annals of the Rheumatic Diseases, 2015, 74, 1636-1644.	0.5	239
6	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.5	215
7	ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. European Journal of Human Genetics, 2020, 28, 1602-1614.	1.4	208
8	Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Annals of the Rheumatic Diseases, 2015, 74, 2043-2049.	0.5	180
9	Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there?. Rheumatology International, $2011, 31, 1-8$.	1.5	177
10	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Annals of the Rheumatic Diseases, 2017, 76, 942-947.	0.5	175
11	Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD. Annals of the Rheumatic Diseases, 2016, 75, 958-964.	0.5	169
12	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. Arthritis and Rheumatology, 2016, 68, 2795-2805.	2.9	168
13	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2015, 74, 635-641.	0.5	145
14	Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. ELife, 2021, 10, .	2.8	145
15	Smoke and autoimmunity: The fire behind the disease. Autoimmunity Reviews, 2016, 15, 354-374.	2.5	143
16	Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. Clinical Rheumatology, 2017, 36, 191-197.	1.0	115
17	Anakinra treatment in drug-resistant Behcet's disease: a case series. Clinical Rheumatology, 2015, 34, 1293-1301.	1.0	114
18	Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD Open, 2015, 1, e000097.	1.8	103

#	Article	IF	CITATIONS
19	Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International) Tj ETQq1 956-964.	1 0.784314 rg 0.8	BT /Overloc 98
20	Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clinical Research in Cardiology, 2012, 101, 525-531.	1.5	97
21	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. Clinical Rheumatology, 2016, 35, 1281-1286.	1.0	95
22	Long-Term Efficacy of Interleukin-1 Receptor Antagonist (Anakinra) in Corticosteroid-Dependent and Colchicine-Resistant Recurrent Pericarditis. Journal of Pediatrics, 2014, 164, 1425-1431.e1.	0.9	94
23	Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS Medicine, 2019, 16, e1002901.	3.9	94
24	Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): State of the art and future perspectives. Autoimmunity Reviews, 2012, 12, 38-43.	2.5	92
25	Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Annals of the Rheumatic Diseases, 2014, 73, 662-667.	0.5	92
26	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Frontiers in Pharmacology, 2017, 8, 369.	1.6	89
27	Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmunity Reviews, 2010, 9, 674-683.	2.5	86
28	Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmunity Reviews, 2014, 13, 1220-1229.	2.5	86
29	Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. Clinical Rheumatology, 2017, 36, 183-189.	1.0	84
30	Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clinical Rheumatology, 2016, 35, 1683-1689.	1.0	83
31	Safety of longâ€term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology, 2015, 62, 40-46.	3.6	82
32	Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives. Mediators of Inflammation, 2015, 2015, 1-21.	1.4	79
33	Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. Autoimmunity Reviews, 2015, 14, 1-9.	2.5	79
34	Diagnosis and classification of relapsing polychondritis. Journal of Autoimmunity, 2014, 48-49, 53-59.	3.0	77
35	International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor–Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care and Research, 2017, 69, 578-586.	1.5	75
36	Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behçet's Disease: A Case Series. Dermatology, 2014, 228, 211-214.	0.9	74

#	Article	IF	Citations
37	Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet's disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology, 2011, 50, 184-188.	0.9	73
38	Recurrent pericarditis: Autoimmune or autoinflammatory?. Autoimmunity Reviews, 2012, 12, 60-65.	2.5	73
39	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Frontiers in Pharmacology, 2016, 7, 380.	1.6	72
40	The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up. Seminars in Arthritis and Rheumatism, 2014, 43, 818-823.	1.6	71
41	Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunologic Research, 2015, 61, 147-153.	1.3	70
42	Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Annals of the Rheumatic Diseases, 2012, 71, 2035-2043.	0.5	69
43	Short- and Long-Term Effects of Spa Therapy in Knee Osteoarthritis. American Journal of Physical Medicine and Rehabilitation, 2010, 89, 125-132.	0.7	68
44	Biological Treatments in Behçet's Disease: Beyond Anti-TNF Therapy. Mediators of Inflammation, 2014, 2014, 1-14.	1.4	68
45	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.5	68
46	Monogenic Autoinflammatory Syndromes: State of the Art on Genetic, Clinical, and Therapeutic Issues. International Journal of Rheumatology, 2013, 2013, 1-15.	0.9	67
47	Ocular Involvement in Systemic Autoimmune Diseases. Clinical Reviews in Allergy and Immunology, 2015, 49, 263-270.	2.9	67
48	Familial Mediterranean fever mutations are hypermorphic mutations that specifically decrease the activation threshold of the Pyrin inflammasome. Rheumatology, 2018, 57, 100-111.	0.9	67
49	Idiopathic Recurrent Pericarditis Refractory to Colchicine Treatment Can Reveal Tumor Necrosis Factor Receptor-Associated Periodic Syndrome. International Journal of Immunopathology and Pharmacology, 2009, 22, 1051-1058.	1.0	65
50	Biological Treatments: New Weapons in the Management of Monogenic Autoinflammatory Disorders. Mediators of Inflammation, 2013, 2013, 1-16.	1.4	64
51	A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. Clinical Rheumatology, 2017, 36, 463-468.	1.0	64
52	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clinical Rheumatology, 2018, 37, 2233-2240.	1.0	64
53	Therapeutic effect of spa therapy and short wave therapy in knee osteoarthritis: a randomized, single blind, controlled trial. Rheumatology International, 2007, 27, 523-529.	1.5	62
54	Autoinflammatory diseases and cardiovascular manifestations. Annals of Medicine, 2011, 43, 341-346.	1.5	61

#	Article	IF	Citations
55	Recurrent pericarditis in children and adolescents. Journal of Cardiovascular Medicine, 2016, 17, 707-712.	0.6	61
56	Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors. Journal of Clinical Medicine, 2018, 7, 504.	1.0	61
57	Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. International Journal of Molecular Sciences, 2019, 20, 1898.	1.8	60
58	Key facts and hot spots on tumor necrosis factor receptorâ€associated periodic syndrome. Clinical Rheumatology, 2014, 33, 1197-1207.	1.0	58
59	Adalimumabâ€Based Treatment Versus Diseaseâ€Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome. Arthritis and Rheumatology, 2018, 70, 1500-1507.	2.9	57
60	Bridging the Gap between the Clinician and the Patient with Cryopyrin-Associated Periodic Syndromes. International Journal of Immunopathology and Pharmacology, 2011, 24, 827-836.	1.0	56
61	Macrophage activation syndrome in the course of monogenic autoinflammatory disorders. Clinical Rheumatology, 2015, 34, 1333-1339.	1.0	56
62	Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clinical Rheumatology, 2019, 38, 407-415.	1.0	56
63	Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. Autoimmunity Reviews, 2015, 14, 90-97.	2.5	55
64	Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives. Current Rheumatology Reports, 2016, 18, 3.	2.1	55
65	A national cohort study on pediatric Behçet's disease: cross-sectional data from an Italian registry. Pediatric Rheumatology, 2017, 15, 84.	0.9	55
66	From the Mediterranean to the Sea of Japan: The Transcontinental Odyssey of Autoinflammatory Diseases. BioMed Research International, 2013, 2013, 1-8.	0.9	54
67	Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. Autoimmunity Reviews, 2016, 15, 447-450.	2.5	54
68	The hereditary autoinflammatory disorders uncovered. Autoimmunity Reviews, 2014, 13, 892-900.	2.5	53
69	Performance of Different Diagnostic Criteria for Familial Mediterranean Fever in Children with Periodic Fevers: Results from a Multicenter International Registry. Journal of Rheumatology, 2016, 43, 154-160.	1.0	52
70	Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study. Clinical Rheumatology, 2017, 36, 451-455.	1.0	52
71	Role of Etanercept in the Treatment of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: Personal Experience and Review of the Literature. International Journal of Immunopathology and Pharmacology, 2010, 23, 701-707.	1.0	51
72	Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa. Medicine (United States), 2015, 94, e1528.	0.4	51

#	Article	IF	CITATIONS
73	Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab. Clinical Rheumatology, 2015, 34, 1141-1143.	1.0	51
74	Validation of a Diagnostic Score for the Diagnosis of Autoinflammatory Diseases in Adults. International Journal of Immunopathology and Pharmacology, 2011, 24, 695-702.	1.0	50
75	Cytokine Signatures in Mucocutaneous and Ocular Behçet's Disease. Frontiers in Immunology, 2017, 8, 200.	2.2	50
76	COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs. Annals of the Rheumatic Diseases, 2021, 80, e14-e14.	0.5	50
77	Drug Retention Rates and Treatment Discontinuation among Anti-TNF- $\langle i \rangle \hat{l} \pm \langle j \rangle$ Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice. Mediators of Inflammation, 2014, 2014, 1-7.	1.4	49
78	Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome. Clinical and Experimental Rheumatology, 2010, 28, 405-7.	0.4	49
79	Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Internal and Emergency Medicine, 2018, 13, 475-489.	1.0	48
80	Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide. Frontiers in Immunology, 2020, 11, 865.	2.2	48
81	Diagnosis of PFAPA syndrome applied to a cohort of 17 adults with unexplained recurrent fevers. Clinical and Experimental Rheumatology, 2012, 30, 269-71.	0.4	48
82	The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: Our experience and review of the literature. Autoimmunity Reviews, 2012, 12, 10-13.	2.5	47
83	Quality of life impairment in Behçet's disease and relationship with disease activity: a prospective study. Internal and Emergency Medicine, 2017, 12, 947-955.	1.0	46
84	The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. Ocular Immunology and Inflammation, 2020, 28, 298-304.	1.0	46
85	Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clinical Rheumatology, 2017, 36, 469-475.	1.0	45
86	Treatment options for periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome in children and adults: a narrative review. Clinical Rheumatology, 2019, 38, 11-17.	1.0	45
87	Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study. British Journal of Ophthalmology, 2018, 102, 637-641.	2.1	44
88	Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases. Annals of the Rheumatic Diseases, 2019, 78, 1405-1411.	0.5	44
89	First Report of Circulating MicroRNAs in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS). PLoS ONE, 2013, 8, e73443.	1.1	44
90	Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF- \hat{l} ± in early phases of the disease. Medicine (United States), 2016, 95, e5516.	0.4	43

#	Article	IF	CITATIONS
91	Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clinical and Experimental Rheumatology, 2010, 28, 802.	0.4	43
92	Simple clinical indicators for early psoriatic arthritis detection. SpringerPlus, 2014, 3, 759.	1.2	42
93	A Comprehensive Overview of the Hereditary Periodic Fever Syndromes. Clinical Reviews in Allergy and Immunology, 2018, 54, 446-453.	2.9	42
94	Influence of baseline modified Rheumatic Disease Comorbidity Index (<scp>mRDCI</scp>) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in realâ€world settings. European Journal of Clinical Investigation, 2018, 48, e13013.	1.7	42
95	Effects of Spa therapy on serum leptin and adiponectin levels in patients with knee osteoarthritis. Rheumatology International, 2011, 31, 879-882.	1.5	41
96	Successful Treatment of Tumor Necrosis Factor Receptor–Associated Periodic Syndrome With Canakinumab. Annals of Internal Medicine, 2012, 156, 907.	2.0	41
97	Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease. Mediators of Inflammation, 2015, 2015, 1-11.	1.4	41
98	Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet's Disease. Ocular Immunology and Inflammation, 2019, 27, 58-63.	1.0	40
99	Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Rheumatology International, 2015, 35, 1943-1947.	1.5	39
100	Safety and Efficacy of Etanercept in Children with Juvenile-Onset Behcet's Disease. International Journal of Immunopathology and Pharmacology, 2009, 22, 551-555.	1.0	38
101	Role of Autoimmunity and Autoinflammation in the Pathogenesis of Idiopathic Recurrent Pericarditis. Clinical Reviews in Allergy and Immunology, 2013, 44, 6-13.	2.9	38
102	Anakinra treatment in patients with gout and type 2 diabetes. Clinical Rheumatology, 2015, 34, 981-984.	1.0	38
103	Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study. Modern Rheumatology, 2017, 27, 1031-1035.	0.9	38
104	The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review. Rheumatology International, 2019, 39, 971-990.	1.5	38
105	Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting. International Immunopharmacology, 2020, 86, 106748.	1.7	38
106	The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. Clinical Rheumatology, 2015, 34, 17-28.	1.0	37
107	Diagnostic Criteria for Adult-Onset Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome. Frontiers in Immunology, 2017, 8, 1018.	2.2	37
108	Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis. Ocular Immunology and Inflammation, 2019, 27, 34-39.	1.0	37

#	Article	IF	Citations
109	A case of resistant adult-onset periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra. Clinical and Experimental Rheumatology, 2012, 30, 593.	0.4	37
110	New therapeutic solutions for Behçet's syndrome. Expert Opinion on Investigational Drugs, 2016, 25, 827-840.	1.9	36
111	Genetic aspects of the antiphospholipid syndrome: An update. Autoimmunity Reviews, 2016, 15, 433-439.	2.5	36
112	Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease. Clinical Rheumatology, 2017, 36, 2063-2069.	1.0	36
113	Current Advances in the Understanding and Treatment of Mevalonate Kinase Deficiency. International Journal of Immunopathology and Pharmacology, 2014, 27, 491-498.	1.0	35
114	The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. Clinical Rheumatology, 2017, 36, 2307-2318.	1.0	35
115	Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clinical Rheumatology, 2018, 37, 2805-2809.	1.0	35
116	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. Frontiers in Pharmacology, 2019, 10, 296.	1.6	35
117	Successful use of canakinumab in a patient with resistant Behçet's disease. Clinical and Experimental Rheumatology, 2012, 30, S115.	0.4	35
118	Clinical and biochemical landmarks in systemic autoinflammatory diseases. Annals of Medicine, 2012, 44, 664-673.	1.5	34
119	The use of TNF-î± blockers in psoriatic arthritis patients with latent tuberculosis infection. Clinical Rheumatology, 2014, 33, 543-547.	1.0	34
120	Safety issues and concerns of new immunomodulators in rheumatology. Expert Opinion on Drug Safety, 2015, 14, 389-399.	1.0	34
121	Effect of hyaluronic acid (MW 500–730kDa) on proteoglycan and nitric oxide production in human osteoarthritic chondrocyte cultures exposed to hydrostatic pressure. Osteoarthritis and Cartilage, 2005, 13, 688-696.	0.6	33
122	Th17 Transcription Factor RORC2 Is Inversely Correlated with FOXP3 Expression in the Joints of Children with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2009, 36, 2017-2024.	1.0	33
123	Retinal Complications of Juvenile Idiopathic Arthritis-related Uveitis: A Microperimetry and Optical Coherence Tomography Study. Ocular Immunology and Inflammation, 2010, 18, 54-59.	1.0	33
124	IL-6 blockade in the management of non-infectious uveitis. Clinical Rheumatology, 2017, 36, 1459-1469.	1.0	33
125	Development and Preliminary Validation of a Diagnostic Score for Identifying Patients Affected with Adult-Onset Autoinflammatory Disorders. International Journal of Immunopathology and Pharmacology, 2010, 23, 1133-1141.	1.0	32
126	Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease. Medicine (United States), 2015, 94, e1858.	0.4	31

#	Article	IF	Citations
127	Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opinion on Biological Therapy, 2015, 15, 641-650.	1.4	31
128	Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin- $1\hat{l}^2$ monoclonal antibody canakinumab. Clinical Rheumatology, 2015, 34, 1311-1316.	1.0	31
129	Clinical Characteristics of Patients Carrying the Q703K Variant of the <i>NLRP3</i> Gene: A 10-year Multicentric National Study. Journal of Rheumatology, 2016, 43, 1093-1100.	1.0	31
130	Canakinumab efficacy in refractory adultâ€onset <scp>PFAPA</scp> syndrome. International Journal of Rheumatic Diseases, 2017, 20, 1050-1051.	0.9	31
131	The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment. Trends in Cardiovascular Medicine, 2021, 31, 265-274.	2.3	31
132	Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clinical and Experimental Rheumatology, 2018, 36, 668-675.	0.4	31
133	Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future. Immunologic Research, 2015, 61, 326-337.	1.3	30
134	Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases. Expert Opinion on Biological Therapy, 2016, 16, 1311-1312.	1.4	30
135	Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. Clinical Rheumatology, 2015, 34, 1817-1820.	1.0	29
136	Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases. Current Cardiology Reports, 2018, 20, 61.	1.3	29
137	Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. Clinical Rheumatology, 2019, 38, 63-70.	1.0	29
138	Long-term clinical course of patients carrying the Q703K mutation in the NLRP3 gene: a case series. Clinical and Experimental Rheumatology, 2012, 30, 943-6.	0.4	29
139	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. Clinical and Experimental Rheumatology, 2021, 39, 187-195.	0.4	29
140	Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis. Autoimmunity Reviews, 2010, 9, 436-440.	2.5	28
141	Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. Journal of Medical Case Reports, 2015, 9, 123.	0.4	28
142	Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clinical Rheumatology, 2016, 35, 2631-2638.	1.0	28
143	Immunometabolic biomarkers of inflammation in Behçet's disease: relationship with epidemiological profile, disease activity and therapeutic regimens. Clinical and Experimental Immunology, 2016, 184, 197-207.	1.1	28
144	PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. Clinical Rheumatology, 2016, 35, 501-505.	1.0	28

#	Article	IF	Citations
145	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.5	27
146	Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. Mediators of Inflammation, 2019, 2019, 1-8.	1.4	27
147	Interleukin-1 Inhibition in Behçet's disease. Israel Medical Association Journal, 2016, 18, 171-6.	0.1	26
148	Untangling the Web of Systemic Autoinflammatory Diseases. Mediators of Inflammation, 2014, 2014, 1-15.	1.4	25
149	Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature. Clinical Rheumatology, 2015, 34, 391-395.	1.0	25
150	Possible chondroprotective effect of canakinumab: An in vitro study on human osteoarthritic chondrocytes. Cytokine, 2015, 71, 165-172.	1.4	25
151	Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Behçet׳s disease. Seminars in Arthritis and Rheumatism, 2016, 46, e1-e2.	1.6	25
152	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. Frontiers in Pharmacology, 2019, 10, 918.	1.6	25
153	Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet's disease. Immunology Letters, 2018, 201, 38-44.	1.1	24
154	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-⟨i⟩α⟨ i⟩ Receptorâ€"Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-12.	1.4	24
155	The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review. Clinical and Experimental Rheumatology, 2013, 31, 141-9.	0.4	24
156	Serum Amyloid A Circulating Levels and Disease Activity in Patients with Juvenile Idiopathic Arthritis. Yonsei Medical Journal, 2012, 53, 1045.	0.9	23
157	Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. Clinical and Experimental Rheumatology, 2016, 34, 531-8.	0.4	23
158	Treatment strategies for childhood noninfectious chronic uveitis: an update. Expert Opinion on Investigational Drugs, 2012, 21, 1-6.	1.9	22
159	Childhood versus adulthood-onset autoinflammatory disorders: myths and truths intertwined. Reumatismo, 2013, 65, 55-62.	0.4	22
160	The purinergic <scp>P</scp> 2×7 receptor is expressed on monocytes in <scp>B</scp> ehçet's disease and is modulated by <scp>TNF</scp> â€i±. European Journal of Immunology, 2014, 44, 227-238.	1.6	22
161	Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. Mediators of Inflammation, 2015, 2015, 1-10.	1.4	22
162	Safety profile of biologic agents for BehÃSet's disease in a multicenter observational cohort study. International Journal of Rheumatic Diseases, 2017, 20, 103-108.	0.9	22

#	Article	IF	CITATIONS
163	Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature. Clinical Rheumatology, 2017, 36, 1687-1690.	1.0	22
164	Sacroileitis and pericarditis: atypical presentation of tumor necrosis factor receptor-associated periodic syndrome and response to etanercept therapy. Clinical and Experimental Rheumatology, 2010, 28, 290-1.	0.4	22
165	Bilateral dexamethasone intravitreal implant in a young patient with Vogt-Koyanagi-Harada disease and refractory uveitis. Clinical Rheumatology, 2015, 34, 1145-1148.	1.0	21
166	Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab. Clinical Rheumatology, 2018, 37, 1715-1720.	1.0	21
167	Clodronate in the management of different musculoskeletal conditions. Minerva Medica, 2018, 109, 300-325.	0.3	21
168	Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease. Annals of the Rheumatic Diseases, 2019, 78, 1736-1737.	0.5	21
169	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. Frontiers in Medicine, 2020, 7, 42.	1.2	21
170	The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2096403.	1.2	21
171	Demographic, clinical and therapeutic findings in a monocentric cohort of adult patients with suspected PFAPA syndrome. Clinical and Experimental Rheumatology, 2016, 34, 77-81.	0.4	21
172	Sulfasalazine-induced immune thrombocytopenia. Postgraduate Medical Journal, 2007, 83, e1-e1.	0.9	20
173	Working the endless puzzle of hereditary autoinflammatory disorders. Modern Rheumatology, 2014, 24, 381-389.	0.9	20
174	Non-canonical manifestations of familial Mediterranean fever: a changing paradigm. Clinical Rheumatology, 2015, 34, 1503-1511.	1.0	20
175	Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clinical Rheumatology, 2015, 34, 807-809.	1.0	20
176	Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts. Arthritis Research and Therapy, 2019, 21, 275.	1.6	20
177	Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI). RMD Open, 2020, 6, e001192.	1.8	20
178	Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis. Mediators of Inflammation, 2020, 2020, 1-5.	1.4	20
179	Efficacy of Alendronate in the Treatment of the SAPHO Syndrome. Journal of Clinical Rheumatology, 2008, 14, 183-184.	0.5	19
180	Colchicine Myopathy and Neuromyopathy. Journal of Clinical Rheumatology, 2010, 16, 229-232.	0.5	19

#	Article	IF	CITATIONS
181	Weekly oral alendronate in mevalonate kinase deficiency. Orphanet Journal of Rare Diseases, 2013, 8, 196.	1.2	19
182	Antiangiogenic VEGF Isoform in Inflammatory Myopathies. Mediators of Inflammation, 2013, 2013, 1-10.	1.4	19
183	Drug survival of adalimumab in patients with rheumatoid arthritis over 10Âyears in the real-world settings: high rate remission together with normal function ability. Clinical Rheumatology, 2016, 35, 2649-2656.	1.0	19
184	Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings. Journal of Rheumatology, 2016, 43, 911-917.	1.0	19
185	The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors. Frontiers in Pharmacology, 2019, 10, 1468.	1.6	19
186	Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. Inflammopharmacology, 2020, 28, 711-718.	1.9	19
187	Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy. Israel Medical Association Journal, 2017, 19, 478-483.	0.1	19
188	Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clinical and Experimental Rheumatology, 2019, 37, 680-683.	0.4	19
189	Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease. Mediators of Inflammation, 2020, 2020, 1-7.	1.4	18
190	Efficacy of anakinra in refractory Behçet's disease sacroiliitis. Clinical and Experimental Rheumatology, 2014, 32, S171.	0.4	18
191	Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders. Israel Medical Association Journal, 2015, 17, 93-7.	0.1	18
192	Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series. Israel Medical Association Journal, 2016, 18, 238-42.	0.1	18
193	Monogenic autoinflammatory syndromes at a dermatological level. Archives of Dermatological Research, 2011, 303, 375-380.	1.1	17
194	Longâ€term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection. International Journal of Dermatology, 2017, 56, 218-220.	0.5	17
195	Hints for Genetic and Clinical Differentiation of Adult-Onset Monogenic Autoinflammatory Diseases. Mediators of Inflammation, 2019, 2019, 1-29.	1.4	17
196	One year in review 2016: novelties in the treatment of rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 357-72.	0.4	17
197	Systemic-onset juvenile idiopathic arthritis complicated by early onset amyloidosis in a patient carrying a mutation in the MEFV gene. Rheumatology International, 2012, 32, 465-467.	1.5	16
198	Update on the Medical Management of Gastrointestinal Behçet's Disease. Mediators of Inflammation, 2017, 2017, 1-11.	1.4	16

#	Article	IF	CITATIONS
199	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor–associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	1.0	16
200	The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still's disease. A systematic review and meta-analysis of observational studies. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093313.	1.2	16
201	INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 783-791.e4.	2.0	16
202	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. Rheumatology, 2022, 61, 4124-4129.	0.9	16
203	Typical and severe tumor necrosis factor receptor–associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series. Rheumatology International, 2012, 32, 4015-4018.	1.5	15
204	The protean ocular involvement in monogenic autoinflammatory diseases: state of the art. Clinical Rheumatology, 2015, 34, 1171-1180.	1.0	15
205	Differential impact of high and low penetrance <i>TNFRSF1A</i> gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome. Journal of Leukocyte Biology, 2016, 99, 761-769.	1.5	15
206	Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review. Rheumatology International, 2018, 38, 25-35.	1.5	15
207	Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. Frontiers in Pharmacology, 2018, 9, 1526.	1.6	15
208	The current status of biological treatment for uveitis. Expert Review of Clinical Immunology, 2020, 16, 787-811.	1.3	15
209	Antirheumatic agents in covid-19: is IL-6 the right target?. Annals of the Rheumatic Diseases, 2021, 80, e2-e2.	0.5	15
210	New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. Mediators of Inflammation, 2020, 2020, 1-6.	1.4	15
211	Evolving Frontiers in the Treatment of Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA) Syndrome. Israel Medical Association Journal, 2017, 19, 444-447.	0.1	15
212	Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy. Clinical and Experimental Rheumatology, 2018, 36, 68-73.	0.4	15
213	Eosinophilia-associated muscle disorders: an immunohistological study with tissue localisation of major basic protein in distinct clinicopathological forms. Journal of Clinical Pathology, 2009, 62, 442-447.	1.0	14
214	Kawasaki syndrome and concurrent Coxsackie virus B3 infection. Rheumatology International, 2012, 32, 4037-4040.	1.5	14
215	Serum amyloid-A in Behçet's disease. Clinical Rheumatology, 2014, 33, 1165-1167.	1.0	14
216	Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms. Clinical Reviews in Allergy and Immunology, 2017, 52, 34-44.	2.9	14

#	Article	IF	CITATIONS
217	Challenges and new horizons in the periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome. Expert Opinion on Orphan Drugs, 2017, 5, 165-171.	0.5	14
218	Serum IFI16 and anti-IFI16 antibodies in psoriatic arthritis. Clinical and Experimental Immunology, 2019, 199, 88-96.	1.1	14
219	Effectiveness of SB5, an Adalimumab Biosimilar, in Patients With Noninfectious Uveitis: A Real-Life Monocentric Experience. Asia-Pacific Journal of Ophthalmology, 2021, 10, 360-365.	1.3	14
220	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis. Ophthalmology and Therapy, 2022, 11, 899-911.	1.0	14
221	Circulating levels of the adipokines vaspin and omentin in patients with juvenile idiopathic arthritis, and relation to disease activity. Clinical and Experimental Rheumatology, 2011, 29, 1044-8.	0.4	14
222	Expanding spectrum of <i><scp>TNFRSF1A</scp></i> gene mutations among patients with idiopathic recurrent acute pericarditis. Internal Medicine Journal, 2013, 43, 725-727.	0.5	13
223	The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experienceÂfromÂa referral center in Italy. Internal and Emergency Medicine, 2017, 12, 605-611.	1.0	13
224	Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet's disease. Internal and Emergency Medicine, 2019, 14, 719-722.	1.0	13
225	Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. Internal and Emergency Medicine, 2020, 15, 1031-1039.	1.0	13
226	Biologic drugs in the treatment of polyarteritis nodosa and deficit of adenosine deaminase 2: A narrative review. Autoimmunity Reviews, 2021, 20, 102784.	2.5	13
227	Relapse of microscopic polyangiitis after vaccination against COVIDâ€19: A case report. Journal of Medical Virology, 2021, 93, 6439-6441.	2.5	13
228	Seronegative reactive spondyloarthritis and the skin. Clinics in Dermatology, 2015, 33, 531-537.	0.8	12
229	Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study. Frontiers in Pharmacology, 2019, 10, 1497.	1.6	12
230	Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF- \hat{l}_{\pm} inhibition: a narrative review. Clinical Rheumatology, 2020, 39, 327-337.	1.0	12
231	Long-Term Outcomes of Behçet's Syndrome-Related Uveitis: A Monocentric Italian Experience. Mediators of Inflammation, 2020, 2020, 1-8.	1.4	12
232	Intramuscular Clodronate in Long-Term Treatment of Symptomatic Knee Osteoarthritis: A Randomized Controlled Study. Drugs in R and D, 2020, 20, 39-45.	1.1	12
233	Inflammatory muscle involvement in systemic vasculitis: A systematic review. Autoimmunity Reviews, 2022, 21, 103029.	2.5	12
234	Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment. Clinical and Experimental Rheumatology, 2009, 27, 890-1.	0.4	12

#	Article	IF	CITATIONS
235	Familial Mediterranean fever diagnosed in an elderly patient. Clinical and Experimental Rheumatology, 2010, 28, S91.	0.4	12
236	Updated overview of molecular pathways involved in the most common monogenic autoinflammatory diseases. Clinical and Experimental Rheumatology, 2018, 36 Suppl 110, 3-9.	0.4	12
237	Partial Rescue of Biochemical Parameters After Hematopoietic Stem Cell Transplantation in a Patient with Prolidase Deficiency Due to Two Novel PEPD Mutations. JIMD Reports, 2011, 3, 71-77.	0.7	11
238	Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 549-555.	0.6	11
239	Longâ€term efficacy and safety of the interleukinâ€1 inhibitors anakinra and canakinumab in refractory Behħet disease uveitis and concomitant bladder papillary carcinoma. Internal Medicine Journal, 2017, 47, 1086-1088.	0.5	11
240	Interleukinâ€1 blockade in neuroâ€ <scp>B</scp> ehçet's disease: a caseâ€based reflection. International Journal of Rheumatic Diseases, 2017, 20, 1046-1049.	0.9	11
241	Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review. Ophthalmology and Therapy, 2021, 10, 777-813.	1.0	11
242	Polymyalgia rheumatica following infective triggersor vaccinations: a different subset of disease?. Reumatologia, 2020, 58, 76-80.	0.5	11
243	One year in review: novelties in the treatment of rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, 102-8.	0.4	11
244	Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. Clinical and Experimental Rheumatology, 2016, 34, 424-9.	0.4	11
245	Development and implementation of the AIDA International Registry for patients with Behçet's disease. Internal and Emergency Medicine, 2022, 17, 1977-1986.	1.0	11
246	Circulating levels of the adipocytokines vaspin and omentin in patients with Kawasaki disease. Rheumatology International, 2012, 32, 1481-1482.	1.5	10
247	The 2014 ACR annual meeting: a bird's eye view of autoimmunity in 2015. Autoimmunity Reviews, 2015, 14, 622-632.	2.5	10
248	Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens. Internal and Emergency Medicine, 2016, 11, 781-791.	1.0	10
249	Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis. Clinical Rheumatology, 2016, 35, 19-23.	1.0	10
250	The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. Scientific Reports, 2021, 11, 12455.	1.6	10
251	Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF- $\hat{l}\pm$ therapy. Clinical and Experimental Rheumatology, 2016, 34, 507-12.	0.4	10
252	Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. Clinical and Experimental Rheumatology, 2019, 37, 762-767.	0.4	10

#	Article	IF	Citations
253	Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome. Frontiers in Medicine, 0, 9, .	1.2	10
254	Severe Macular Edema in Patients with Juvenile Idiopathic Arthritis-Related Uveitis. Case Reports in Ophthalmological Medicine, 2013, 2013, 1-5.	0.3	9
255	Bone status of children born from mothers with autoimmune diseases treated during pregnancy with prednisone and/or low molecular weight heparin. Pediatric Rheumatology, 2014, 12, 47.	0.9	9
256	Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis. Medicine (United States), 2015, 94, e1170.	0.4	9
257	Management of Small Vessel Vasculitides. Current Rheumatology Reports, 2016, 18, 36.	2.1	9
258	Lights and shadows in autoinflammatory syndromes from the childhood and adulthood perspective. Clinical Rheumatology, 2016, 35, 565-572.	1.0	9
259	Development of de novo major involvement during follow-up in Behçet's syndrome. Clinical Rheumatology, 2016, 35, 247-250.	1.0	9
260	Rapid desensitization to anakinraâ€related delayed reaction: Need for a standardized protocol. Journal of Dermatology, 2017, 44, 981-982.	0.6	9
261	Auditory involvement in Behcet's disease: relationship with demographic, clinical, and therapeutic characteristics. Clinical Rheumatology, 2017, 36, 445-449.	1.0	9
262	Magnetic resonance imaging of the sacroiliac joints in SpA: with or without intravenous contrast media? A preliminary report. Radiologia Medica, 2019, 124, 1142-1150.	4.7	9
263	A novel grey scale and Power Doppler ultrasonographic score for idiopathic inflammatory myopathies: Siena Myositis Ultrasound Grading Scale. Rheumatology, 2021, 61, 185-194.	0.9	9
264	Bone-sparing effects of rituximab and body composition analysis in aÂcohort of postmenopausal women affected by rheumatoid arthritis – retrospective study. Reumatologia, 2021, 59, 206-210.	0.5	9
265	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis. Ophthalmology and Therapy, 2022, 11, 887-897.	1.0	9
266	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. Frontiers in Medicine, 2022, 9, 878797.	1.2	9
267	Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering. Frontiers in Immunology, 2022, 13, 860877.	2.2	9
268	Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA network. Internal and Emergency Medicine, 2021, 16, 2163-2171.	1.0	8
269	Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behçet's Syndrome. Ophthalmology and Therapy, 2021, 10, 1129-1135.	1.0	8
270	Genotype–phenotype associations in familial Mediterranean fever: a study of 500 Egyptian pediatric patients. Clinical Rheumatology, 2022, 41, 1511-1521.	1.0	8

#	Article	IF	Citations
271	Leptin, adiponectin, resistin, visfatin serum levels and idiopathic recurrent pericarditis: biomarkers of disease activity? A preliminary report. Clinical and Experimental Rheumatology, 2013, 31, 207-12.	0.4	8
272	Serum immunoglobulin D levels in patients with Beh $ ilde{A}$ Set's disease according to different clinical manifestations. Clinical and Experimental Rheumatology, 2018, 36, 110-115.	0.4	8
273	Efficacy of anti-tumour necrosis factor- \hat{l}_{\pm} monoclonal antibodies in patients with non-infectious anterior uveitis. Clinical and Experimental Rheumatology, 2019, 37, 301-305.	0.4	8
274	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. Clinical and Experimental Rheumatology, 2021, 39, 187-195.	0.4	8
275	Efficacy of cyclosporine A treatment in relapsing febrile lobular panniculitis associated with small vessel vasculitis. Rheumatology International, 2010, 30, 797-799.	1.5	7
276	What Do Cytokine Profiles Tell Us About Subsets of Juvenile Idiopathic Arthritis?. Current Rheumatology Reports, 2012, 14, 150-154.	2.1	7
277	Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort. Arthritis Research and Therapy, 2020, 22, 278.	1.6	7
278	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-6.	1.4	7
279	Large pericardial effusion in a family with recurrent pericarditis: A report of probable x-linked transmission. Experimental and Clinical Cardiology, 2011, 16, 54-6.	1.3	7
280	The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort. Seminars in Arthritis and Rheumatism, 2022, 52, 151957.	1.6	7
281	Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection. Clinical and Experimental Rheumatology, 2016, 34, 353.	0.4	7
282	Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. Clinical and Experimental Rheumatology, 2017, 35, 93-97.	0.4	7
283	Intravitreal Dexamethasone Implant as an Adjunct Weapon for Severe and Refractory Uveitis in Behçet's Disease. Israel Medical Association Journal, 2017, 19, 415-419.	0.1	7
284	Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. Israel Medical Association Journal, 2018, 20, 438-441.	0.1	7
285	Neutrophil Extracellular Traps in ANCA-Associated Vasculitis and Interstitial Lung Disease: A Scoping Review. Life, 2022, 12, 317.	1.1	7
286	Serosal Involvement in Adult-Onset Autoinflammatory Disorders. Respiration, 2010, 80, 260-261.	1.2	6
287	Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration. Pediatric Rheumatology, 2014, 12, 49.	0.9	6
288	Blau syndrome and latent tubercular infection: an unresolved partnership. International Journal of Rheumatic Diseases, 2014, 17, 586-587.	0.9	6

#	Article	IF	CITATIONS
289	The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis. Mediators of Inflammation, 2020, 2020, 1-9.	1.4	6
290	Safety of systemic treatments for Behçet's syndrome. Expert Opinion on Drug Safety, 2020, 19, 1269-1301.	1.0	6
291	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndromeâ€"Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. Frontiers in Medicine, 2021, 8, 668173.	1.2	6
292	Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110336.	1.2	6
293	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. Clinical Rheumatology, 2022, 41, 641-647.	1.0	6
294	Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting with refractory chronic arthritis. Clinical and Experimental Rheumatology, 2015, 33, S171-2.	0.4	6
295	Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's Syndrome. Frontiers in Medicine, 2021, 8, 769870.	1.2	6
296	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2021, 39, 227-227.	0.4	6
297	Improved Efficacy of Intramuscular Weekly Administration of Clodronate 200Âmg (100Âmg Twice) Tj ETQq1 1 0.7 Osteoporosis. Clinical Drug Investigation, 2013, 33, 193-198.	'84314 rg 1.1	BT /Overloc 5
298	Caution Should be Used in the Recognition of Adult-Onset Autoinflammatory Disorders: Facts or Fiction?. Frontiers in Immunology, 2013, 4, 96.	2.2	5
299	The potential role of bone scintigraphy in the detection of deep muscular fascia involvement and calcinosis cutis in anti-synthetase syndrome. International Journal of Rheumatic Diseases, 2013, 16, 495-496.	0.9	5
300	Delights and letâ€downs in the management of tumor necrosis factor receptorâ€associated periodic syndrome: the canakinumab experience in a patient with a highâ€penetrance T50M <i><scp>TNFRSF</scp>1A</i> variant. International Journal of Rheumatic Diseases, 2015, 18, 473-475.	0.9	5
301	The common NOD2/CARD15 variant P268S in patients with non-infectious uveitis: a cohort study. Pediatric Rheumatology, 2015, 13, 38.	0.9	5
302	Developing a Predictive Score for Chronic Arthritis among a Cohort ofÂChildren with Musculoskeletal Complaints—The Chronic Arthritis ScoreÂStudy. Journal of Pediatrics, 2016, 169, 188-193.	0.9	5
303	Power and spectral Doppler ultrasound in suspected active sacroilitis: a comparison with magnetic resonance imaging as gold standard. Rheumatology, 2021, 60, 1338-1345.	0.9	5
304	Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Clinical and Experimental Rheumatology, 2012, 30, S108-14.	0.4	5
305	Adult-onset autoinflammatory disorders: a still debated entity?. Clinical and Experimental Rheumatology, 2015, 33, 137-40.	0.4	5
306	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. Clinical and Experimental Rheumatology, 2017, 35, 660-665.	0.4	5

#	Article	IF	CITATIONS
307	Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behçet's disease. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 130-131.	0.4	5
308	Adult-onset Still's disease with elderly onset, results from a multicentre study. Clinical and Experimental Rheumatology, 2022, , .	0.4	5
309	Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. Rheumatology, 2021, 60, 5705-5712.	0.9	4
310	Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3218-3220.e1.	2.0	4
311	Anakinra effectiveness in refractory polyserositis: An Italian multicenter study. Joint Bone Spine, 2022, 89, 105299.	0.8	4
312	The eye involvement in monogenic autoinflammatory diseases: literature review and update. Clinical and Experimental Rheumatology, 2018, 36 Suppl 110, 44-53.	0.4	4
313	Effectiveness of TNF-α blockade in the treatment of refractory non-infectious scleritis: a multicentre study. Clinical and Experimental Rheumatology, 2020, 38, 1138-1144.	0.4	4
314	Pediatric Scleritis: An Update. Ocular Immunology and Inflammation, 2023, 31, 175-184.	1.0	4
315	Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases. Frontiers in Medicine, 0, 9, .	1.2	4
316	Atypical Juvenile Polymyositis. Journal of Clinical Rheumatology, 2008, 14, 309-310.	0.5	3
317	Autoinflammatory disorders and patients with isolated serosal involvement. Rheumatology International, 2011, 31, 979-980.	1.5	3
318	Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Beh \tilde{A} set's disease. Pediatric Rheumatology, 2015, 13, .	0.9	3
319	Systemic Vasculopathy in a Patient With Tumor Necrosis Factor Receptor–Associated Periodic Syndrome. Journal of Clinical Rheumatology, 2017, 23, 395-397.	0.5	3
320	Anterior chest wall non-traumatic diseases: a road map for the radiologist. Acta Biomedica, 2020, 91, 43-50.	0.2	3
321	Canakinumab in recessive dystrophic epidermolysis bullosa: a novel unexpected weapon for non-healing wounds?. Clinical and Experimental Rheumatology, 2016, 34, 961-962.	0.4	3
322	Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet's Disease. Israel Medical Association Journal, 2018, 20, 517-521.	0.1	3
323	Retention rate of IL-1 inhibitors in Schnitzler's syndrome. Clinical and Experimental Rheumatology, 0, ,	0.4	3
324	Resolution of Schnitzler's syndrome after haematopoietic stem cell transplantation. Clinical and Experimental Rheumatology, 2021, 39, 704-704.	0.4	3

#	Article	IF	CITATIONS
325	Methods Used to Assess Clinical Outcome and Quality of Life in Osteoarthritis. Seminars in Arthritis and Rheumatism, 2004, 34, 70-72.	1.6	2
326	Possible Implication of Local Immune Response in Darier's Disease: An Immunohistochemical Characterization of Lesional Inflammatory Infiltrate. Mediators of Inflammation, 2010, 2010, 1-8.	1.4	2
327	Role of nerve growth factor and tropomyosin receptor kinase A in the pathogenesis of osteoarthritis. Might nerve growth factor be the link interwinding obesity and osteoarthritis?. Annals of the Rheumatic Diseases, 2015, 74, e70-e70.	0.5	2
328	Observations about subcalcaneal adventitial bursitis (heel fat pad inflammatory lesion) in rheumatoid arthritis. Comment on the article of Suzuki and Shirai. Reumatismo, 2020, 72, 182-183.	0.4	2
329	Inflammatory Bowel Diseases and Coexisting Spondyloarthritis: A Neglected and too Often Under-Reported Association by Radiologists. A Multicenter Study by Italian Research Group of Imaging in Rheumatology. Gastroenterology Insights, 2020, 11, 47-57.	0.7	2
330	Giant cell arteritis presenting as aÂstroke in the internal carotid artery territory: aÂcase-based review. Reumatologia, 2021, 59, 121-125.	0.5	2
331	Difference in pain and accuracy of two hyaluronic acid injection techniques for symptomatic knee osteoarthritis in overweight patients. Reumatologia, 2021, 59, 23-26.	0.5	2
332	Low muscle mass and body composition analysis in aÂgroup of postmenopausal women affected by primary Sjögren's syndrome. Reumatologia, 2021, 59, 153-160.	0.5	2
333	Diffuse Peripheral Enthesitis in Metabolic Syndrome: A Retrospective Clinical and Power Doppler Ultrasound Study. ReumatologÃa ClÃnica, 2022, 18, 273-278.	0.2	2
334	Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection. Internal and Emergency Medicine, 2022, 17, 475-480.	1.0	2
335	OP0273â€ADHERENCE TO COLCHICINE TREATMENT AND COLCHICINE RESISTANCE IN A MULTICENTRIC FMF NATIONAL COHORT. Annals of the Rheumatic Diseases, 2020, 79, 170-171.	0.5	2
336	Neridronate for transient osteoporosis of the hip in a child. Osteoporosis International, 2022, 33, 1619-1624.	1.3	2
337	Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis. Clinical and Experimental Rheumatology, 2017, 35, 170-171.	0.4	2
338	Effectiveness of rituximab in bullous Sweet's syndrome. International Journal of Dermatology, 2022, ,	0.5	2
339	Adalimumab for refractory idiopathic scleritis in children. Clinical and Experimental Rheumatology, 0, , .	0.4	2
340	Doppler and Spectral Ultrasound of Sacroiliac Joints in Pediatric Patients with Suspected Juvenile Spondyloarthritis. Diagnostics, 2022, 12, 992.	1.3	2
341	Superb microvascular imaging in giant cell arteritis. Clinical and Experimental Rheumatology, 2022, , .	0.4	2
342	THU0376â€Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Annals of the Rheumatic Diseases, 2013, 71, 282.3-283.	0.5	1

#	Article	IF	CITATIONS
343	AB0037â€Serum cytokine signature in mucocutaneous and ocular behÇet's disease. , 2017, , .		1
344	AB0709â€Switching from originator infliximab to biosimilar infliximab: efficacy and safety in a cohort of patients with established beh‡et's disease. , 2018, , .		1
345	Autoinflammatory Diseases. , 2018, , 371-377.		1
346	Comment on: Muscle fluorodeoxyglucose uptake assessed by positron emission tomography-computed tomography as a biomarker of inflammatory myopathies disease activity. Rheumatology, 2019, 60, e270-e271.	0.9	1
347	Ultrasound evaluation of the scapholunate ligament and scapholunate joint space in patients with wrist complaints in a rheumatologic setting. Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ,-SzopiÅ"ska, 2021, 21, e105-e111.	0.7	1
348	Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110371.	1.2	1
349	POS0661â€RAPID RESPONSE TO BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUAT RESPONSE TO METHOTREXATE AND AT LEAST ONE BIOLOGIC DMARD: A CLINICAL AND POWER DOPPLER ULTRASOUND STUDY. Annals of the Rheumatic Diseases, 2021, 80, 573.1-573.	E 0.5	1
350	OP0093â€RETENTION RATE OF IL-1 INHIBITORS IN PATIENTS WITH SCHNITZLER'S SYNDROME. Annals of th Rheumatic Diseases, 2021, 80, 51-52.	^e 0.5	1
351	Anti-dense fine speckled 70 antibodies in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 326.	0.4	1
352	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2021, 39, 227.	0.4	1
353	Polidistrectual videocapillaroscopic evaluation in a patient with prolidase deficiency. Clinical and Experimental Rheumatology, 2020, 38, 1265-1266.	0.4	1
354	Routine IgG4 staining in minor salivary gland biopsy in a cohort of Italian Caucasian patients suffering from xerostomia. Reumatologia, 2022, 60, 12-15.	0.5	1
355	Polymyalgia Rheumatica: A syndrome with an enthesitic subset? Comment on: "Use of 18F FDG PET-CT to discriminate polymyalgia rheumatica and atypical spondylarthritis in clinical practice―by Marie Pean de Ponfilly–Sotier et al. Joint Bone Spine 2021;89:105325. Joint Bone Spine, 2022, 89, 105378.	0.8	1
356	Erratum to "Effect of hyaluronic acid (MW 500–730 kDa) on proteoglycan and nitric oxide production in human osteoarthritic chondrocyte cultures exposed to hydrostatic pressure―[Osteoarthritis Cartilage 13 (2005) 688–696]. Osteoarthritis and Cartilage, 2006, 14, 504-505.	0.6	0
357	SAT0466â€PED-BD COHORT 2013: Expert Consensus Classification Gives Higher Sensitivity than the International Study Group Criteria to Define Behcet's Disease in Children. Annals of the Rheumatic Diseases, 2013, 72, A739.1-A739.	0.5	O
358	AB1226â€Leptin, adiponectin, resistin, visfatin serum levels and idiopathic recurrent pericarditis: A preliminary report. Annals of the Rheumatic Diseases, 2013, 71, 707.18-708.	0.5	0
359	SATO564â€Articular Involvement in Behçet Disease: An Ultrasonographic Study. Annals of the Rheumatic Diseases, 2016, 75, 873.2-873.	0.5	O
360	THU0155â€Impact of baseline modified rheumatic disease comorbidity index (MRDCI) on drug survival and effectiveness of biological drugs in patients affected with rheumatoid arthritis (RA), spondyloarthritis (SPA), and psoriatic arthritis (PSA) in real-world settings. , 2017, , .		0

#	Article	IF	CITATIONS
361	THU0541â€Role of IL-1 inhibition in adult onset still's disease (AOSD): a retrospective, observational multicentric study from the italian society of rheumatology study group on autoinflammatory diseases. , 2017, , .		O
362	AB1160â€Epidemiology and clinical presentation of ocular involvement in a population of 278 patients with non infectious uveitis. , 2017, , .		0
363	THU0517â€THE LONGITUDINAL EUROFEVER PROJECT: AN UPDATE ON ENROLLMENT. , 2019, , .		O
364	Response to: †Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?†by Fayand et al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2019-216862.	0.5	0
365	POS1349â€THE JOINT INVOLVEMENT IN ADULT ONSET STILL'S DISEASE IS CHARACTERISED BY A PECULIAR MAGNETIC RESONANCE IMAGING AND A SPECIFIC TRANSCRIPTOMIC PROFILE. Annals of the Rheumatic Diseases, 2021, 80, 957.1-957.	0.5	O
366	POS0832â€A NOVEL GREY SCALE AND POWER DOPPLER ULTRASONOGRAPHIC SCORE FOR IDIOPATHIC INFLAMMATORY MYOPATHIES: SIENA MYOSITIS ULTRASOUND GRADING SCALE. Annals of the Rheumatic Diseases, 2021, 80, 669.1-670.	0.5	0
367	POS0963â€POWER AND SPECTRAL DOPPLER ULTRASOUND AS A SCREENING TOOL IN THE DIAGNOSTIC COUR OF SUSPECTED AXIAL SPONDYLOARTHRITIS: PRELIMINARY DATA FROM A LARGE MONOCENTRIC COHORT. Annals of the Rheumatic Diseases, 2021, 80, 746.2-747.	0.5	O
368	ABO380â€MACHINE LEARNING CAN PREDICT GIANT CELL ARTERITIS RELAPSE AFTER GLUCOCORTICOID TAPERIN Annals of the Rheumatic Diseases, 2021, 80, 1217-1217.	√6: ₅	0
369	SAT0307â€Impact of the modified rheumatic disease comorbidity index(MRDCI) on drug survival of first line anti-tnff drugs in patents affected with psoriatic arthritis in real life setting. , 2018, , .		O
370	SAT0223â€Predictive factors of early failure to first line treatment with methotrexate in patients with rheumatoid arthritis. results from the gisea registry , 2018, , .		0
371	SAT0193â€Early discontinuation of first line biological treatment with etanercept in patients with rheumatoid arthritis: results from the italian gisea registry. , 2018, , .		O
372	FRI0075â€Risk of hepatitis b infection reactivation in rheumatic diseases patients treated with anti-cd20 therapy. , 2018, , .		0
373	AB0281â€SAFETY AND RETENTION RATE AFTER SWITCHING FROM ETANERCEPT ORIGINATOR (ETN) TO ETANERCEPT BIOSIMILAR (SB4) IN INFLAMMATORY JOINT DISEASES: DATA FROM REAL LIFE Annals of the Rheumatic Diseases, 2020, 79, 1439.1-1440.	0.5	O
374	THU0520â€DIFFUSE ENTHESITIS AND LOW-GRADE INFLAMMATION IN PATIENTS WITH METABOLIC SYNDROME CLINICAL AND ULTRASOUND STUDY Annals of the Rheumatic Diseases, 2020, 79, 499.1-499.	: 6. ₅	0
375	FRIO457â€LONG-TERM OUTCOMES AND TREATMENT EFFICACY IN PATIENTS WITH TNF RECEPTOR-ASSOCIATED AUTOINFLAMMATORY SYNDROME (TRAPS) FROM THE EUROFEVER INTERNATIONAL REGISTRY. Annals of the Rheumatic Diseases, 2020, 79, 825.2-826.) 0.5	O
376	AB1086â€POWER DOPPLER AND SPECTRAL DOPPLER ULTRASOUND IN SUSPECTED ACTIVE SACROILIITIS: A COMPARISON WITH MAGNETIC RESONANCE IMAGING AS GOLD STANDARD. Annals of the Rheumatic Diseases, 2020, 79, 1832.1-1832.	0.5	O
377	AB0939â€POLYMYALGIA RHEUMATICA FOLLOWING INFECTIVE TRIGGERS OR VACCINATIONS: A DIFFERENT SUBSET OF DISEASE?. Annals of the Rheumatic Diseases, 2020, 79, 1769.3-1769.	0.5	O
378	SAT0243â€SUBPHENOTYPES IN POLYARTERITIS NODOSA (PAN): TARGET ORGAN ASSOCIATIONS OF A WORLDWIDE COLLABORATION STUDY. Annals of the Rheumatic Diseases, 2020, 79, 1064-1065.	0.5	0

#	Article	IF	CITATIONS
379	KL-6 in ANCA-Associated Vasculitis Patients with and without ILD: A Machine Learning Approach. Biology, 2022, 11, 94.	1.3	O
380	Effects of tumor necrosis factor-α inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitis. Clinical and Experimental Rheumatology, 2015, 33, 411-3.	0.4	0
381	Efficacy and safety of abatacept in a patient with rheumatoid arthritis and concomitant Staphylococcus aureus osteomyelitis. Clinical and Experimental Rheumatology, 2015, 33, 947-8.	0.4	0
382	Circulating intercellular adhesion molecule 1 (sICAM-1) in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). Clinical and Experimental Rheumatology, 2017, 35 Suppl 104, 13-14.	0.4	0
383	Musculoskeletal manifestations in hereditary periodic fever syndromes. Clinical and Experimental Rheumatology, 2018, 36 Suppl 110, 25-31.	0.4	0
384	Differential serum levels of interleukin-37 in patients with tumour necrosis factor receptor-associated periodic syndrome (TRAPS). Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 159-160.	0.4	0
385	Efficacy of monoclonal anti-tumour necrosis factor-α antibodies in uveitic macular oedema. Clinical and Experimental Rheumatology, 2020, 38, 621-625.	0.4	0
386	Reply to Praprotnik and Tomsic and erratum corrige. Clinical and Experimental Rheumatology, 2020, 38, 1034.	0.4	0
387	Resolution of Schnitzler's syndrome after haematopoietic stem cell transplantation. Clinical and Experimental Rheumatology, 2021, 39, 704.	0.4	0
388	Efficacy of intravenous neridronate in transient osteoporosis of the hip. Clinical and Experimental Rheumatology, 0 , , .	0.4	0
389	Atypical Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient with Polymyalgia Rheumatica and Giant Cell Arteritis. Current Health Sciences Journal, 2021, 47, 306-309.	0.2	0
390	Retention rate of IL-1 inhibitors in Schnitzler's syndrome Clinical and Experimental Rheumatology, 2022, , .	0.4	0
391	Efficacy of intravenous neridronate in transient osteoporosis of the hip Clinical and Experimental Rheumatology, 2022, , .	0.4	0
392	Adalimumab for refractory idiopathic scleritis in children Clinical and Experimental Rheumatology, 2022, , .	0.4	0
393	OUP accepted manuscript. Rheumatology, 2022, , .	0.9	0
394	Diffuse Peripheral Enthesitis in Metabolic Syndrome: A Retrospective Clinical and Power Doppler Ultrasound Study. ReumatologÃa ClÃnica (English Edition), 2022, 18, 273-278.	0.2	0
395	Accuracy of power Doppler ultrasonography in the diagnosis and monitoring of idiopathic inflammatory myopathies. Rheumatology, 0, , .	0.9	0